Kiniksa Pharmaceuticals International, plc (KNSA) vs Regencell Bioscience Holdings Limited (RGC)
- Kiniksa Pharmaceuticals International, plc KNSA 78.59 −1.69%
- Regencell Bioscience Holdings Limited RGC 9.59 +0.74%
Kiniksa Pharmaceuticals International, plc and Regencell Bioscience Holdings Limited are both Drug Manufacturers Specialty & Generic companies. Kiniksa Pharmaceuticals International, plc is the larger, with a market value of $6.2B against $4.7B — 1.3× the size. Regencell Bioscience Holdings Limited has negative trailing earnings, so its P/E is not meaningful; Kiniksa Pharmaceuticals International, plc trades at 73.4×. Kiniksa Pharmaceuticals International, plc has the higher net margin (9.59% vs 0.00%) and the higher return on invested capital (48.9% vs 0.00%). Across the 11 metrics below, Kiniksa Pharmaceuticals International, plc leads on 10 and Regencell Bioscience Holdings Limited on 1.
Valuation
Profitability
| Metric | KNSA | RGC | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 89.82% | — | 53.94% |
| Operating margin | 11.92% | — | 0.00% |
| Net margin | 9.59% | 0.00% | 0.00% |
| Free cash flow margin | 21.74% | 0.00% | 0.00% |
| Return on equity | 14.04% | 0.00% | (0.40%) |
| Return on assets | 10.36% | 0.00% | (3.32%) |
| Return on invested capital | 48.87% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack